Association of long‐term tacrolimus (FK506) therapy with abnormal megakaryocytosis, bone marrow fibrosis, and dyserythropoiesis

Clinical Case Reports

Zhongbo Yang¹  Thomas Loew² 

[1] Department of Pathology and Anatomic Sciences, University of Missouri, Columbia, Missouri;Department of Hematology and Oncology, University of Missouri, Columbia, Missouri

关键词: Dyserythropoiesis;    fibrosis;    megakaryocytois;    tacrolimus;   

DOI  :  10.1002/ccr3.303

来源: Wiley

【 摘 要 】

Key Clinical Message

Haematopoietic abnormalities associated with tacrolimus are relatively rare with reversible pure red cell aplasia being the most common. We report for the first time, to our best knowledge, tacrolimus therapy associated with bone marrow fibrosis, abnormal megakaryocytosis, and dyserythopoiesis in a 17-year-old male treated with tacrolimus for nephrotic syndrome.

【 授权许可】

CC BY-NC   
© 2015 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.